Bright Minds Biosciences (DRUG) Net Cash Flow (2019 - 2026)

Bright Minds Biosciences (DRUG) has 7 years of Net Cash Flow data on file, last reported at $159.9 million in Q1 2026.

• Quarterly Net Cash Flow rose 8553.58% year-over-year to $159.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $180.4 million (up 379.88% YoY) and the FY2025 annual result came in at $55.9 million, up 7429.91% from the prior year.
• Net Cash Flow advanced to $159.9 million in Q1 2026, from $5.4 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $159.9 million in Q1 2026 to a low of -$15.3 million in Q3 2022.
• A 5-year average of $12.1 million and a median of $1.2 million in 2023 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2025 — Net Cash Flow slumped 4178.12% — and 2026, when it surged 8553.58%.
• Tracing DRUG's Net Cash Flow over 5 years: stood at $3.6 million in 2022, then slumped by 65.53% to $1.2 million in 2023, then soared by 2968.79% to $38.3 million in 2024, then plunged by 85.83% to $5.4 million in 2025, then surged by 2842.94% to $159.9 million in 2026.
• The last three Net Cash Flow figures came in at $159.9 million (Q1 2026), $5.4 million (Q4 2025), and $23.3 million (Q3 2025), per Business Quant data.